Marcio Debiasi
Overview
Explore the profile of Marcio Debiasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vasconcelos de Matos L, Debiasi M, Padrao T, Sousa B, Cardoso F
Breast
. 2024 Sep;
78:103793.
PMID: 39232267
Introduction: The KEYNOTE-522 (KN-522) trial showed that the addition of pembrolizumab to standard chemotherapy improved pathological complete response (pCR) and event-free survival (EFS) for patients with early triple negative breast...
2.
Vasconcelos de Matos L, Volovat S, Debiasi M, Cardoso F
Breast
. 2023 Sep;
72:103576.
PMID: 37696110
Breast cancer in men is rare, but a relevant public health issue, yielding a 25% higher risk of mortality comparing to female counterparts. The representation of males in clinical trials...
3.
Vaz S, Graff S, Ferreira A, Debiasi M, de Geus-Oei L
Cancers (Basel)
. 2023 May;
15(9).
PMID: 37174086
Significant advances in breast cancer (BC) treatment have been made in the last decade, including the use of immunotherapy and, in particular, immune checkpoint inhibitors that have been shown to...
4.
Nunes Filho P, Albuquerque C, Capella M, Debiasi M
Oncol Ther
. 2023 Mar;
11(2):171-183.
PMID: 36917399
Breast cancer is the most frequently diagnosed malignancy in patients worldwide and the main cause of cancer-related death. Though still incurable, metastatic breast cancer's prognosis has been considerably improved in...
5.
Brandao M, Maurer C, Ziegelmann P, Ponde N, Ferreira A, Martel S, et al.
ESMO Open
. 2020 Aug;
5(4).
PMID: 32847835
Background: Several endocrine therapy (ET)-based treatments are available for patients with advanced breast cancer. We assessed the efficacy of different ET-based treatments in patients with hormone receptor-positive/HER2-negative advanced breast cancer...
6.
Monteiro F, Soares A, Debiasi M, Schutz F, Maluf F, Bastos D, et al.
Clin Genitourin Cancer
. 2020 Apr;
18(4):244-251.e4.
PMID: 32303427
Combination treatments with immuno-oncology (IO) agents and IO agents plus a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) have been approved for first-line treatment of patients with metastatic...
7.
Brandao M, Debiasi M, de Azambuja E
Lancet Oncol
. 2019 May;
20(5):e234-e235.
PMID: 31044711
No abstract available.
8.
Werutsky G, Hochhegger B, Lopes de Figueiredo Pinto J, Martinez-Mesa J, Zanini M, Herz Berdichevski E, et al.
BMC Cancer
. 2019 Jan;
19(1):5.
PMID: 30606144
Background: The present study aims to assess the performance of 18F-FDG PET-CT on mediastinal staging of non-small cell lung cancer (NSCLC) in a location with endemic granulomatous infectious disease. Methods:...
9.
Guindalini R, Zheng Y, Abe H, Whitaker K, Yoshimatsu T, Walsh T, et al.
Clin Cancer Res
. 2018 Aug;
25(6):1786-1794.
PMID: 30154229
Purpose: To establish a cohort of high-risk women undergoing intensive surveillance for breast cancer. We performed dynamic contrast-enhanced MRI every 6 months in conjunction with annual mammography (MG). Eligible participants...
10.
Debiasi M, Polanczyk C, Ziegelmann P, Barrios C, Cao H, Dignam J, et al.
Front Oncol
. 2018 Jun;
8:156.
PMID: 29872641
Background: Several (neo)adjuvant treatments for patients with HER2-positive breast cancer have been compared in different randomized clinical trials. Since it is not feasible to conduct adequate pairwise comparative trials of...